CAM
HRTX icon

Cresset Asset Management’s Heron Therapeutics HRTX Stock Holding History

Cresset Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,390
Closed -$17.4K – 1712
2025
Q4 		$17.4K Buy
+13,390
New +$16.5K ﹤0.01% 1648
2019
Q2 		– Sell
-94
Closed -$2K – 997
2019
Q1 		$2K Hold
94
– – ﹤0.01% 1647
2018
Q4 		$2K Buy
+94
New +$2.58K ﹤0.01% 1315

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Cresset Asset Management's HRTX Position: Q1 2026 in Review

Cresset Asset Management sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 13,390 shares — an estimated $17.4K sold.

Cresset Asset Management first reported a position in HRTX in Q4 2018 and held it in 3 quarters. The position peaked at $17.4K in Q4 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Cresset Asset Management reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Cresset Asset Management sold 13,390 Heron Therapeutics shares in Q1 2026, an estimated $17.4K.
  • Cresset Asset Management first reported a position in Heron Therapeutics in Q4 2018 and held it in 3 quarters.
  • Cresset Asset Management's Heron Therapeutics position peaked at $17.4K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.